Next Article in Journal
Efficient Extraction of Fermentation Inhibitors by Means of Green Hydrophobic Deep Eutectic Solvents
Previous Article in Journal
In Vitro Evaluation of the Anti-Diabetic Potential of Aqueous Acetone Helichrysum petiolare Extract (AAHPE) with Molecular Docking Relevance in Diabetes Mellitus
Previous Article in Special Issue
Chalcones as Promising Antitumor Agents by Targeting the p53 Pathway: An Overview and New Insights in Drug-Likeness
Review

Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype

1
Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal
2
Associate Laboratory i4HB—Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal
*
Authors to whom correspondence should be addressed.
Academic Editor: Clementina Manera
Molecules 2022, 27(1), 156; https://doi.org/10.3390/molecules27010156
Received: 30 November 2021 / Revised: 20 December 2021 / Accepted: 23 December 2021 / Published: 28 December 2021
(This article belongs to the Special Issue Nature-Inspired Antitumor Agents )
Although cannabinoids have been used for centuries for diverse pathological conditions, recently, their clinical interest and application have emerged due to their diverse pharmacological properties. Indeed, it is well established that cannabinoids exert important actions on multiple sclerosis, epilepsy and pain relief. Regarding cancer, cannabinoids were first introduced to manage chemotherapy-related side effects, though several studies demonstrated that they could modulate the proliferation and death of different cancer cells, as well as angiogenesis, making them attractive agents for cancer treatment. In relation to breast cancer, it has been suggested that estrogen receptor-negative (ER) cells are more sensitive to cannabinoids than estrogen receptor-positive (ER+) cells. In fact, most of the studies regarding their effects on breast tumors have been conducted on triple-negative breast cancer (TNBC). Nonetheless, the number of studies on human epidermal growth factor receptor 2-positive (HER2+) and ER+ breast tumors has been rising in recent years. However, besides the optimistic results obtained thus far, there is still a long way to go to fully understand the role of these molecules. This review intends to help clarify the clinical potential of cannabinoids for each breast cancer subtype. View Full-Text
Keywords: cannabinoids; Cannabis sativa; anandamide; Δ9-tetrahydrocannabinol; cannabidiol; cannabigerol; cannabinol; cannabidivarin; breast cancer cannabinoids; Cannabis sativa; anandamide; Δ9-tetrahydrocannabinol; cannabidiol; cannabigerol; cannabinol; cannabidivarin; breast cancer
Show Figures

Figure 1

MDPI and ACS Style

Almeida, C.F.; Teixeira, N.; Correia-da-Silva, G.; Amaral, C. Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype. Molecules 2022, 27, 156. https://doi.org/10.3390/molecules27010156

AMA Style

Almeida CF, Teixeira N, Correia-da-Silva G, Amaral C. Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype. Molecules. 2022; 27(1):156. https://doi.org/10.3390/molecules27010156

Chicago/Turabian Style

Almeida, Cristina F., Natércia Teixeira, Georgina Correia-da-Silva, and Cristina Amaral. 2022. "Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype" Molecules 27, no. 1: 156. https://doi.org/10.3390/molecules27010156

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop